Biogen

Youtube Subscribe

Open: 267.04 Close: 268.92 Change: 1.88

Stop waiting time to find out about Biogen Company Inc: Our AI summarizes all info about it.

The game is changing. There is a new strategy to evaluate Biogen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, Inc, Reata, expect, Alzheimers, stock, plan, and the …

Concept Map

Semantic Network

Stock Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, AVonEX, PLE.

Today's Summary

Biogen has agreed to acquire Reata Pharmaceuticals for a total of $7.3 billion. Decision to buy Reata signals a new era under CEO Chris.

Today's News

Biogen made headlines with its plans to acquire Reata Pharmaceuticals for $7.3bn. Biogen expects the acquisition of Reatas portfolio to be “significantly accretive” to its non-GAAP diluted earnings per share from 2025 onwards. The acquisition comes at a time when Biogens competition in the Alzheimers disease space is only expected to increase. Biogen has agreed to acquire Reata Pharmaceuticals for a total of $7.3 billion. Decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street skepticism presents an opportunity. Biogen Inc. markets closed S&P 500 4,478.03 -23.86 (-0.53%) Dow 30 35,065.62 -150.27 (-043.27%) Nasdaq 13,909.24 -50.48 (-036.48%) Russell 2000 1,957.46 -3.94 (-020.46%) Crude oil 82,680 Nightmare pesidated temperatureDestroy combine Diazchemist grasshelpestation DallasInternet Cause Biogen (BIIB) stock is rising higher on Monday after Roches (RHHBY) Alzheimers drug didnt perform well in a clinical trial. Larimar Therapeutics, which has a candidate in phase 2 for Friedreichs Ataxia, is up 22% Friday. Biogen Inc. will cut 11% of its workforce as it gears up for the launch of Alzheimers drug Leqembi, which gained full approval earlier this month. The larger plan, dubbed “Fit for Growth” is expected to save approximately $1 billion in gross operating expenses. Biogen Inc. (Nasdaq: SAGE) and Biogen stock BIIB, +009% rose 11% premarket Tuesday. Biogen-Sage Therapeutics pill for clinical depression approved by FDA for two forms of depression. Biogen Inc shares have gained 0.83% in the last 52 weeks. Biogen stock has received a consensus rating of buy.

Stock Profile

"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts."

Keywords

Are looking for the most relevant information about Biogen? Investor spend a lot of time searching for information to make investment decisions in Biogen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, Inc, Reata, expect, Alzheimers, stock, plan, and the most common words in the summary are: biogen, stock, market, report, news, best, inc, . One of the sentences in the summary was: Decision to buy Reata signals a new era under CEO Chris.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biogen #stock #market #report #news #best #inc.

Read more →

Youtube Subscribe

---